Dimerix Limited (ASX:DXB) | US Patent Granted for Dimerix New Asset DMX-652

Dimerix (ASX:DXB) has secured a United States composition of matter patent for its recently acquired Phase 2 ready drug candidate DMX 652, extending patent protection until 11 April 2043 while preparations continue for a Phase 2 trial in acute kidney injury associated with cardiac surgery. We break down what the patent grant covers, the clinical development package acquired with the asset, and the next milestones disclosed by the company.